NCT05049343View on ClinicalTrials.gov

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

November 20, 2021

Study Completion Date

December 3, 2021

Conditions
Healthy Volunteer
Interventions
DRUG

SAGE-904

SAGE-904 oral solution.

DRUG

Placebo

Placebo oral solution.

DRUG

Ketamine

Ketamine intravenous (IV) infusion.

Trial Locations (1)

07103

Sage Investigational Site, Newark

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants | Biotech Hunter | Biotech Hunter